Rise in Prevalence of Cancer Propelled T-cell Therapy Market
- T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for application in immunotherapy. Both the first two FDA-approved CAR-T therapies target the CD19 antigen, which is found on many types of B-cell cancers. Kymriah is approved to treat relapsed/refractory B-cell precursor acute lymphoblastic leukemia and Yescarta is approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Growing prevalence of cancer across the world and increase in cancer research & development drive the market. According to the WHO, the number of global cancer deaths is projected to increase by 45% between 2008 and 2030. It is also estimated that by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low- and middle-income countries.
Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure of T-cell Therapy Market Report
Key Drivers and Restraints of Global T-cell Therapy Market
- Increase in investment in adoptive T-cell transfer approaches of disease treatment drives the market. Furthermore, technological advancements in manufacturing processes and developments in CAR T-cell therapy for solid tumors fuel the revenue generation. The approvals and clinical success of Kymriah and Yescarta opened new and encouraging avenues for developers of cellular immunotherapies.
- High prices of therapies are likely to limit the market growth in the near future. The CAR T therapy costs range between US$ 373,000 and US$ 475,000 per infusion. The reimbursement gap remains unsustainable and is a huge impediment to patient access. In the U.S., CMS recently raised reimbursement of the total cost of CAR T-cell therapies from 50% to 65%, effective from 2020.
CAR T-cell Therapy Estimated to Dominate Global T-cell Therapy Market
- Based on type, the global T-cell therapy market can be divided into: CAR T-cell Therapy, T-cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based
- The CAR T-cell therapy segment dominated the global T-cell therapy market in terms of revenue generation in 2018 and is expected to lead the position during the forecast period. Large number of research institutions and companies are doing clinical studies with different CAR-T products that often target the same condition.
- In 2018, Kymriah, which is a T-cell therapy for the treatment of acute lymphoblastic leukemia, was manufactured for more than 300 patients intended to be used across 11 countries and 35 certified treatment centers. On the other hand, by June 2018, around 61 cancer centers were authorized for Yescarta administration to patients, which is the first CAR T therapy for adults living with certain types of non-Hodgkin lymphoma. Rise in number of research & development activities boosts the market growth.
Solid Tumors Segment to Witness Highest Growth
- Based on indication, the global T-cell therapy market can be divided into: Hematologic Malignancies and Solid Tumors. The hematologic malignancies segment is sub-segmented into lymphoma, leukemia, and myeloma. The solid tumors segment is further segmented into melanoma, brain & central nervous system, liver cancer, and others.
- In terms of indication, the hematologic malignancies segment dominated the global T-cell therapy market in 2018. CAR T-cell therapy has efficiently proven its effectiveness for hematologic malignancies, especially diffuse B-cell lymphoma (DBCL). Over 25,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed annually in the U.S., representing an incidence rate of 6.9 per 100,000.
- However, solid tumors offer tenfold greater opportunity than hematological cancers with possibly 1.3 million cancer patients annually. Effective and affordable CAR-T for solid tumors treatment offers benefits to patients and substantial investment returns to market entities.
North America to Dominate Global T-cell Therapy Market
- In terms of region, the global T-cell therapy market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- In terms of revenue, North America dominated the T-Cell therapy market in 2018, followed by Europe, due to high number of sponsors from the U.S. for clinical trials, large number of research institute presence, and the U.S. FDA approval of CAR T-cell therapeutics in the U.S. and Canada. In August 2017, the first chimeric antigen receptor T-cell (CAR-T cell) therapy was approved for the market in the U.S. for targeted cancer immunotherapy, and CAR-T cell therapy developers have recently gained entry into the market in Europe as well.
- Asia Pacific is expected to grow at the highest CAGR during the forecast period. Rise in number of clinical trials pertaining to CAR T-cell therapies and increase in number of diseases are anticipated to boost the growth of the market in this region.
Looking for Regional Analysis or Competitive Landscape in T-cell Therapy Market, Ask for a Customized Report
Key Manufacturers Operating in Market
The global T-cell therapy market was highly fragmented in 2018. Key manufacturers operating in the global market are:
- Novartis AG
- Gilead Sciences, Inc.
- TCR2 Therapeutics Inc.
- Sorrento Therapeutics, Inc.
- Fate Therapeutics
- Merck KGaA
- Celgene Corporation
T-Cell Therapy Market: Research Scope
T-Cell Therapy Market, by Type
- CAR T-cell Therapy
- T-cell Receptor (TCR)-based
- Tumor Infiltrating Lymphocytes (TIL)-based
T-Cell Therapy Market, by Indication
- Hematologic Malignancies
- Solid Tumors
- Brain & Central Nervous System
- Liver Cancer
T-Cell Therapy Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.